Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined
with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver
mutation non- squamous non-small cell lung cancer